UCSF

How High Altitude Changes Your Body's Metabolism

Retrieved on: 
Tuesday, March 7, 2023

SAN FRANCISCO, March 7, 2023 /PRNewswire/ -- Compared to those of us who live at sea level, the 2 million people worldwide who live above 4,500 meters (or 14,764 feet) of elevation—about the height of Mount Rainier, Mount Whitney, and many Colorado and Alaska peaks—have lower rates of metabolic diseases such as diabetes, coronary artery disease, hypercholesterolemia, and obesity.

Key Points: 
  • The work, published in the journal Cell Metabolism, not only helps explain the metabolic differences of people who live at high altitude, but could also lead to new treatments for metabolic disease.
  • "We hope these findings will help us identify metabolic switches that might be beneficial for metabolism even outside of low-oxygen environments."
  • In general, these more lasting changes mirror what has been seen in humans who live at high altitude.
  • "We already see athletes going to train at altitude to improve their athletic performance; maybe in the future, we'll start recommending that people spend time at high altitude for other health reasons," says Midha.

Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 2, 2023

DURHAM, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided an operational update.

Key Points: 
  • Following the monetization of TEMBEXA, we have a strong balance sheet to fully fund Chimerix into 2027, including through potential approval of ONC201.
  • “As we look to 2023, we are making tremendous progress and continuing our strong execution to advance ONC201 towards regulatory approval.
  • General and administrative expenses increased to $5.3 million for the fourth quarter of 2022, compared to $5.2 million for the same period in 2021.
  • Chimerix will host a conference call and live audio webcast to discuss fourth quarter and full-year 2022 financial results and provide a business update today at 8:30 a.m.

Vivalink's Biometrics Data Platform Supports UCSF Clinical Trial for Hypertrophic Cardiomyopathy (HCM)

Retrieved on: 
Wednesday, March 1, 2023

CAMPBELL, Calif., March 1, 2023 /PRNewswire/ -- UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink's Biometrics Data Platform. The study, consisting of 70 patients, will evaluate if regimented moderate intensity exercise improves overall exercise capacity and cardiac blood flow.

Key Points: 
  • CAMPBELL, Calif., March 1, 2023 /PRNewswire/ -- UC San Francisco (UCSF) is conducting a six-month clinical trial on hypertrophic cardiomyopathy (HCM) using Vivalink 's Biometrics Data Platform.
  • The reusable sensor will continually capture ECG and heart rate data 24 hours a day which will be processed through Vivalink's Biometrics Data Platform .
  • "We are thrilled to support UCSF in this clinical trial for HCM," said Jiang Li, CEO of Vivalink.
  • "Our Biometrics Data Platform is a reliable and accurate way to study key cardiovascular and health conditions.

Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

Retrieved on: 
Wednesday, March 1, 2023

PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.  

Key Points: 
  • PITTSBURGH, March 1, 2023 /PRNewswire/ -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the creation of a Scientific Advisory Board in oral health.
  • The five-member Board will initially focus on the development of LP-310, Lipella's product candidate for the treatment of symptomatic oral lichen planus (OLP).
  • Members of the advisory board include:
    Alessandro Villa, DDS, PhD, MPH will serve as the inaugural Chair of the Scientific Advisory Board.
  • Dr. Villa is the Chief of Oral Medicine, Oral Oncology and Dentistry at Miami Cancer Institute and Professor, Herbert Wertheim College of Medicine, Miami, FL.

Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022

Retrieved on: 
Wednesday, March 1, 2023

WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.

Key Points: 
  • WESTPORT, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.
  • R&D costs increased by approximately $0.6 million, or approximately 32%, from approximately $1.9 million in the Fiscal 2022 Quarter, to approximately $2.5 million in the Fiscal 2023 Quarter.
  • The Fiscal 2022 Quarter included $0.6 million for bonuses to employees and consultants, reflected in payroll-related expenses, which was approved and paid in the Fiscal 2022 Quarter.
  • The Fiscal 2023 Quarter also included director’s fees of $0.1 million (director’s fees were approved and commenced January 2022).

ABVC BioPharma Provides 2023 Pipeline Update

Retrieved on: 
Tuesday, February 28, 2023

FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.

Key Points: 
  • FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today provided an update to drug and medical device developments expected in 2023.
  • ABVC expects to initiate the Phase II study in the fourth quarter of 2023 and then compare the results to Wellbutrin XL, a commonly used medicine to treat cancer patients suffering with depression.
  • The clinical study for ABV-1702 for myelodysplastic syndrome is expected to start in Q4 of 2023.
  • In addition, ABVC intends to submit ABV-1703’s Phase II clinical trial IND to the Taiwan FDA after commencing clinical trials in the United States.

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

Retrieved on: 
Monday, February 27, 2023

WESTPORT, Conn., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it will host a key opinion leader (KOL) webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at 10:30 am Eastern Time.

Key Points: 
  • A critical mechanism of cancer immune evasion is the generation of high levels of immunosuppressive adenosine within the tumor microenvironment.
  • Portage’s virtual KOL event will discuss what can be learned from agents that target adenosine for the treatment of cancer, and how Portage plans to augment an immune response with its next-generation small molecule adenosine 2A and adenosine 2B inhibitors.
  • Lawrence Fong, M.D., is the Efim Guzik Distinguished Professor in Cancer Biology and leads the Cancer Immunotherapy Program at UCSF.
  • He also co-directs the Parker Institute for Cancer Immunotherapy at UCSF and co-leads the Cancer Immunology Program in the Helen Diller Family Comprehensive Cancer Center.

GeoVax Vaccine Data Included in HIV-Therapy Presentation at the Conference on Retroviruses and Opportunistic Infections

Retrieved on: 
Monday, February 27, 2023

ATLANTA, GA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the presentation of results from a clinical study of a combinational HIV therapy that included GeoVax’s HIV vaccine candidate, MVA62B. The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.

Key Points: 
  • The data were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) held February 19-22, 2023, in Seattle, Washington.
  • The data indicated very high levels of immunogenicity of the treatment, particularly the induction of T cell immunity, even though HIV infection compromises the immune system.
  • “The GeoVax MVA62B was previously tested in multiple clinical trials as a component of vaccine regimens designed to induce immune responses that prevent HIV infection.
  • We are continuing development of the GeoVax MVA-VLP vaccine platform targeting multiple viral diseases, including COVID-19, MPOX, Smallpox and hemorrhagic fever viruses, such as Lassa Fever and Ebola.”

Dr. Rana Baroudi Celebrates the Launch of Her New Website

Retrieved on: 
Thursday, February 23, 2023

SAN JOSE, Calif., Feb. 23, 2023 /PRNewswire-PRWeb/ -- Dr. Rana Baroudi is happy to announce the launch of her practice's new website. The site allows patients to learn more about the services she offers, the practice as a whole, and her background in the field. It is now also easier than ever to contact her office directly to book an appointment. This includes the ability to fill out forms and request appointments online.

Key Points: 
  • SAN JOSE, Calif., Feb. 23, 2023 /PRNewswire-PRWeb/ -- Dr. Rana Baroudi is happy to announce the launch of her practice's new website.
  • Dr. Baroudi believes that all clinicians owe it to their patients to stay on the cutting edge of their specialty.
  • To learn more about Dr. Rana Baroudi's dental practice, contact her office today by visiting https://baroudiperio.com/contact/ or calling 408-265-6501.
  • Rana Baroudi, Dr Rana Baroudi - Periodontics and Dental Implants, 1 408-265-6501, [email protected]

Women of Global Change launches the WGC Gateway Program Empowering US Women-Owned Business

Retrieved on: 
Thursday, February 23, 2023

LAS VEGAS, Feb. 23, 2023 /PRNewswire-PRWeb/ -- Women are over half the world's population yet still lack leadership positions.

Key Points: 
  • To facilitate the creation of such businesses, Women of Global Change is presenting the WGC Gateway Program on April 28th & 29th, 2023.
  • Women of Global Change (WGC) is a multiple White House award-winning 501(c) 3 organization that leads with service.
  • Dr. Dame Shellie Hunt founded the Women of Global Change, and the WGC has had a powerful impact on the lives of people all over the world.
  • To find out more about the women of global change, go to http://www.womenofglobalchange.com
    To explore the WGC Gateway Program, go to: Gateway